Eli Lilly touts a 'constellation' of successes with their PhII Alzheimer’s study — but disappointing failures drag down shares
Eli Lilly’s research division whipped up considerable fervor for its Phase II top-line readout on its next-gen Alzheimer’s drug donanemab. But after spelling out the data this weekend, you can expect some of the experts in the field to adopt a much more measured attitude about its chances of a regulatory approval.
Lilly had heralded a statistically significant result for the novel primary endpoint: change from baseline in the 76-week score on the integrated Alzheimer’s Disease Rating Scale, or iADRS, which is a combined score on cognition and function that indicated the N3pG beta amyloid drug could slow the decline of early-stage patients, which was eagerly consumed in an area of R&D with millions of patients who currently have nothing to address the memory-wasting ailment.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.
